Screening for acute hepatic porphyria in postural tachycardia syndrome
Clinical Autonomic Research · 2025
DOI: 10.1007/s10286-025-01153-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Autonomic Research, 2025. Verfasst von Naome Mwesigwa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 506 Robinson Research Building, Nashville, TN, 37232…. Hauptthemen laut MEDLINE: Postural Orthostatic Tachycardia Syndrome, Porphyrias, Hepatic. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alnylam Pharmaceuticals.
Abstract (Originalsprache)
Purpose
Postural orthostatic tachycardia syndrome (POTS) is characterized by an excessive heart rate increase upon standing, often associated with dizziness, gastrointestinal symptoms, and decreased functional capacity. Acute hepatic porphyrias (AHP) are rare metabolic disorders with nonspecific neurovisceral and autonomic symptoms, some of which overlap with POTS. The purpose of this study was to evaluate AHP by molecular and biochemical testing in patients with POTS.
Methods
We studied 50 patients diagnosed with POTS and gastrointestinal symptoms at the Vanderbilt Autonomic Dysfunction Center. They underwent neuro-hormonal evaluation for POTS and genetic and biochemical screening for AHP. Genetic testing was aimed mainly at the four genes relevant to AHPs. Porphobilinogen (PBG), delta-aminolevulinic acid (ALA), and total porphyrins were measured in urine with normalization to creatinine.
Results
The average age of the patients was 33 ± 8.6 years, 96% were female, and the average BMI was 28 ± 7.2 kg/m 2 , average systolic blood pressure was 120 ± 15.5 mmHg, average heart rate was 77 ± 13.6 bpm at baseline, and average SBP was 126 ± 19.1 mmHg. A heart rate of 111 ± 15.8 bpm at 10 min upright, showed normal cardiovascular reflexes. The COMPASS-31 total score was 32 ± 8.4, with a normal autonomic function test. Urine PBG averaged 1 ± 0.7 mg/g creatinine, ALA 2 ± 0.9 mg/g creatinine, and total porphyrins 172 ± 74.2 mmol/g creatinine, which were all normal. None had variants in the four genes associated with AHPs. Three patients were heterozygous for a common low expression ferrochelatase gene variant (FECH).
Conclusions
We found no evidence of AHP in patients with POTS with uncontrolled gastrointestinal symptoms, suggesting that screening for AHP, a rare genetic disorder, may not be warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 506 Robinson Research Building, Nashville, TN, 37232-880, USA.
- Galveston Porphyria Laboratory, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
- Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 506 Robinson Research Building, Nashville, TN, 37232-880, USA. cyndya.shibao@vumc.org.
Förderung
- Alnylam Pharmaceuticals
Zitieren
APA
Mwesigwa, N., Williamson, H., Turner, S., Pouya, M. E., Ding, T., Pedro, O. J., Anderson, K. E., & Shibao, C. A. (2025). Screening for acute hepatic porphyria in postural tachycardia syndrome. Clinical Autonomic Research. https://doi.org/10.1007/s10286-025-01153-5
Vancouver
Mwesigwa N, Williamson H, Turner S, Pouya ME, Ding T, Pedro OJ, et al. Screening for acute hepatic porphyria in postural tachycardia syndrome. Clinical Autonomic Research. 2025. doi:10.1007/s10286-025-01153-5
BibTeX
@article{Mwesigwa2025,
author = {Mwesigwa, Naome and Williamson, Hadley and Turner, Shalonda and Pouya, Mehr E and Ding, Tan and Pedro, Ortiz J and Anderson, Karl E and Shibao, Cyndya A},
title = {Screening for acute hepatic porphyria in postural tachycardia syndrome},
journal = {Clinical Autonomic Research},
year = {2025},
doi = {10.1007/s10286-025-01153-5}
}
EUVIMED